

CLAIMS:

1. A therapy for the treatment of cancer comprising administering to a patient in need thereof a polymer-taxane conjugate and one or more of group comprising a
5 camptothecin, gemcitabine, raltitrexed, cyclophosphamide, vinorelbine tartrate, flavopiridol, imatinib mesylate, epirubicin, fluorouracil, mesna, bleomycin, vinorelbine or gefitinib.
2. The therapy of claim 1, wherein the polymer of said polymer-taxane conjugate is poly-l-glutamate and the taxane of said polymer-taxane conjugate is paclitaxel.
- 10 3. The therapy of claim 2, wherein said polymer-taxane conjugate is administered at 175, 210, 225, 235 or 250 mg/m² paclitaxel equivalents in combination with gemcitabine administered at 1250 mg/m².
4. The therapy of claim 3, further comprising radiation therapy.
5. The therapy of claim 3, further comprising administering vinorelbine at 30 mg/m².
- 15 6. The therapy of claim 5, further comprising radiation therapy.
7. The therapy of claim 3, further comprising administering carboplatin administered at AUC=5 or 6 or cisplatin administered at 75 or 80mg/m².
8. The therapy of claim 7, further comprising radiation therapy.
9. The therapy of claim 7, further comprising vinorelbine administered at 30 mg/m².
- 20 10. The therapy of claim 9, further comprising radiation therapy.
11. The therapy of claim 2, wherein said polymer-taxane conjugate is administered at 175, 210, 225, 235 or 250 mg/m² paclitaxel equivalents in combination with vinorelbine administered at 30 mg/m².
12. The therapy of claim 11, further comprising radiation therapy.
- 25 13. A therapy for the treatment of cancer comprising administering to a patient in need thereof a polymer-taxane conjugate wherein said polymer-taxane conjugate is administered at 175, 210, 225, 235 or 250 mg/m² paclitaxel equivalents in combination with carboplatin administered at AUC=5 or 6 or cisplatin administered at 75 or 80mg/m².
- 30 14. The therapy of claim 13, further comprising radiation therapy.
15. The therapy of claim 13, further comprising administering vinorelbine at 30 mg/m².

16. The therapy of claim 15, further comprising radiation therapy.
17. The therapy of claim 13, wherein the polymer of said polymer-taxane conjugate is poly-l-glutamate and the taxane of said polymer-taxane conjugate is paclitaxel.
18. The therapy of claim 17, further comprising radiation therapy.
- 5 19. The therapy of claim 17, further comprising administering vinorelbine at 30 mg/m².
20. The therapy of claim 19, further comprising radiation therapy.